News Incyte Corporation

Stocks

INCY

US45337C1027

Pharmaceuticals

Real-time Estimate Cboe BZX Other stock markets 18:07:29 20/07/2026 BST			5-day change	1st Jan Change
115.63 ^USD	-1.38%		+1.29%	+17.14%

02:09pm	Halozyme Therapeutics, Incyte Sign Deal to Develop Subcutaneous Formulations of Blood Cancer Drug	MT
01:47pm	Goldman Sachs Adjusts Price Target on Incyte to $110 From $100, Maintains Neutral Rating	MT

All News

Mentions Relevance

01:47pm	Goldman Sachs Adjusts Price Target on Incyte to $110 From $100, Maintains Neutral Rating	MT
07-17	Incyte Data to Be Highlighted in Four Rapid Oral Presentations at the European Society for Medical Oncology (ESMO) Congress 2026 Support Efforts to Improve Outcomes in Difficult-to-Treat Cancers	BU
07-15	BofA Securities Raises Incyte Price Target to $136 From $124	MT
07-14	Barclays Adjusts Incyte Price Target to $134 From $117, Maintains Overweight Rating	MT
07-13	BMO Capital Adjusts Price Target on Incyte to $112 From $94, Maintains Market Perform Rating	MT
07-13	Jefferies Adjusts Price Target on Incyte to $105 From $100, Maintains Hold Rating	MT
07-13	Incyte Presents Phase 1/2 Multidose Data for Vga039 (Latarcibart) At Isth 2026 Showing Substantial Bleed Reductions in Patients with All Von Willebrand Disease Types	CI
07-13	Incyte's Latarcibart Cuts Bleeding Rates in Phase 1/2 Trial in Patients With von Willebrand Disease	MT
07-13	Incyte Presents Phase 1/2 Multidose Data for VGA039 (Latarcibart) at ISTH 2026, Showing Substantial Bleed Reductions in Patients with all Von Willebrand Disease Types	BU
07-08	Incyte to Report Second Quarter Financial Results	BU
07-07	RBC Capital Adjusts Incyte Price Target to $99 From $95, Maintains Sector Perform Rating	MT
07-06	Incyte Corporation completed the acquisition of Vega Therapeutics, Inc. from Star OpCo, Inc.	CI
07-06	Incyte Completes Acquisition of Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding its Hematology Portfolio	BU
06-29	Incyte Corporation(NasdaqGS:INCY) dropped from Russell Midcap Growth Benchmark	CI
06-29	Incyte Corporation(NasdaqGS:INCY) dropped from Russell 3000E Growth Benchmark	CI
06-29	Incyte Corporation(NasdaqGS:INCY) dropped from Russell 1000 Growth Benchmark	CI
06-29	Incyte Corporation(NasdaqGS:INCY) dropped from Russell 1000 Growth-Defensive Index	CI
06-28	Incyte Corporation(NasdaqGS:INCY) dropped from Russell 1000 Dynamic Index	CI
06-28	Incyte Corporation(NasdaqGS:INCY) dropped from Russell 3000 Growth Benchmark	CI
06-26	European Medicines Agency Panel Backs Label Expansion for Incyte's Opzelura	MT
06-26	UBS Adjusts Price Target on Incyte to $113 From $103, Maintains Neutral Rating	MT
06-26	Incyte Receives Positive Chmp Opinion for Opzelura (Ruxolitinib) Cream for Treatment of Moderate Atopic Dermatitis in Adults	CI
06-26	Incyte's Opzelura Advances Toward EU Approval for Atopic Dermatitis	MT
06-26	Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis	BU
06-25	UBS Adjusts Price Target on Incyte to $113 From $103	MT